0001855763-23-000007.txt : 20231030 0001855763-23-000007.hdr.sgml : 20231030 20231030123047 ACCESSION NUMBER: 0001855763-23-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231026 FILED AS OF DATE: 20231030 DATE AS OF CHANGE: 20231030 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BUNKA CHRISTOPHER CENTRAL INDEX KEY: 0001103780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39874 FILM NUMBER: 231358844 MAIL ADDRESS: STREET 1: 1924 BIRKDALE AVE CITY: KELOWNA STATE: A1 ZIP: V1P1R7 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexaria Bioscience Corp. CENTRAL INDEX KEY: 0001348362 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202000871 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 BUSINESS PHONE: 250-765-6424 MAIL ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 FORMER COMPANY: FORMER CONFORMED NAME: LEXARIA CORP. DATE OF NAME CHANGE: 20080229 FORMER COMPANY: FORMER CONFORMED NAME: Lexaria Corp. DATE OF NAME CHANGE: 20051229 4 1 primary_doc.xml PRIMARY DOCUMENT X0508 4 2023-10-26 0 0001348362 Lexaria Bioscience Corp. LEXX 0001103780 BUNKA CHRISTOPHER 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 BRITISH COLUMBIA, CANADA 1 1 0 0 Chief Executive Officer 0 common shares 273543 D common shares 254412 I Private Holding Company Warrants 10.5 2020-05-06 2025-05-06 Common Shares 6667 6667 I Private Holding Company Stock Options 3 2021-04-26 2026-04-26 Common Shares 26000 32667 D Stock Options 3 2021-06-08 2026-06-08 Common Shares 23334 56001 D Stock Options 3 2021-09-01 2026-09-01 Common Shares 15000 71001 D Stock Options 2.91 2022-08-29 2027-08-29 Common Shares 30000 101001 D Stock Options 1.15 2023-10-26 4 A 0 30000 0 A 2023-10-26 2028-10-26 Common Shares 30000 131001 D Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023 Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023 /Chris Bunka/ 2023-10-30